May 31, 2012
Kyowa Hakko Kirin launched on May 29 its first antibody drug Poteligeo Injection 20 mg (recombinant mogamulizumab) for the treatment of relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma (ATL). The company’s medical representatives (MRs), among approximately 1,400 MRs, who have...read more